DURHAM – Adhera Therapeutics, a specialty pharmaceutical company leveraging technology to commercialize drug therapeutics for hypertension, has raised more than $3.2 million in debt.
The money was raised from 45 investors — with a minimum $10,000 investment accepted from any outside investor, according to the recent SEC filing.
The round is capped at $7 million, with $3.7 million remaining to be sold.
According to its website, Adhera has its own patented technology platform, DyrctAxess, which is “secure, web-based, HIPPA-compliant.”
It offers direct prescription delivery and real-time monitoring and communications between patients and physicians, among other things.
The company also has the commercial product Prestalia, which is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform.
The firm said a portion of the proceeds raised would be used for general corporate purposes, including to pay executive salaries.
Since 2010, the company has raised more $67 million in both debt and equity.
